title: Clinical outcome and olanzapine plasma levels in acute schizophrenia.
abstract: OBJECTIVE
  This open label study was performed to evaluate the relationship between the plasma concentration of olanzapine and the response in acute schizophrenic inpatients.
  
  
  METHODS
  A total of 54 inpatients, 38 males and 16 females, age ranging from 18 to 75 years, affected by Schizophrenia (DSM IV criteria) during an exacerbation phase were included in the study. Olanzapine (OLZ) was started at a dose of 5-20 mg/day and was increased to a mean dose of 15.27 mg +/-5.53 S.D. Patients were evaluated at baseline, and after 2 weeks, by using BPRS, PANNS, HRS-D, EPSE, and ACS.
  
  
  RESULTS
  BPRS and total PANSS showed a statistically significant improvement at the end of the study. Olanzapine plasma levels (PL) ranged from 5 to 120 ng/ml (mean 33.15 ng/ml +/- 28.28 S.D.) and showed a positive correlation with OLZ dosage. A significant curvilinear correlation between OLZ PL and clinical improvement (BPRS, PANSS and HRS-D percent of amelioration) was observed.
  
  
  CONCLUSIONS
  Olanzapine plasma level determination seems to be a useful tool in optimizing acute treatment particularly for more problematic cases.
authors.affiliation: Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, IRCCS Ospedale Maggiore, Via F. Sforza 35, 20122 Milan, Italy. maurimc@policlinico.mi.it
authors.forename: M C
authors.initials: MC
authors.lastname: Mauri
authors.forename: C P C
authors.initials: CP
authors.lastname: Steinhilber
authors.forename: R
authors.initials: R
authors.lastname: Marino
authors.forename: E
authors.initials: E
authors.lastname: Invernizzi
authors.forename: A
authors.initials: A
authors.lastname: Fiorentini
authors.forename: G
authors.initials: G
authors.lastname: Cerveri
authors.forename: M L
authors.initials: ML
authors.lastname: Baldi
authors.forename: F
authors.initials: F
authors.lastname: Barale
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine